EI
ACER

EAM Investors’s Acer Therapeutics Inc ACER Stock Holding History

EAM Investors’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-21,773
Closed -$671K – 339
2018
Q3 		$671K Buy
+21,773
New +$583K 0.1% 279

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's ACER Position: Q4 2018 in Review

EAM Investors sold out of Acer Therapeutics Inc (ACER) in Q4 2018, closing a stake of 21,773 shares — an estimated $671K sold.

EAM Investors first reported a position in ACER in Q3 2018 and held it in 1 quarter. The position peaked at $671K in Q3 2018. 28 funds tracked by Wall St. Rank hold ACER as of Q4 2018.

  • EAM Investors reported no remaining Acer Therapeutics Inc position as of Q4 2018 after selling out during the quarter.
  • EAM Investors sold 21,773 Acer Therapeutics Inc shares in Q4 2018, an estimated $671K.
  • EAM Investors first reported a position in Acer Therapeutics Inc in Q3 2018 and held it in 1 quarter.
  • EAM Investors's Acer Therapeutics Inc position peaked at $671K in Q3 2018.
  • 28 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2018.

Based on EAM Investors's 13F filing for Q4 2018, filed 13 Feb 2019.